Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delia Preti

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Handbook of Experimental Pharmacology|January 29, 2019
NOP-Targeted Peptide LigandsDelia Preti, Girolamo Caló, Remo Guerrini
Expert Opinion on Therapeutic Patents|June 7, 2012
TRP channels as therapeutic targets in airway disorders: a patent reviewDelia Preti, Arpad Szallasi, Riccardo Patacchini
Pharmaceutical Patent Analyst|April 9, 2015
Transient receptor potential ankyrin 1 (TRPA1) antagonistsDelia Preti, Giulia Saponaro, Arpad Szallasi
Nature Chemical Biology|May 23, 2024
PROTAC-ing tuberculosisDelia Preti, Valentina Albanese, Peggy Carla Raffaella Marconi
Journal of Medicinal Chemistry|April 2, 2010
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agentsPier Giovanni Baraldi, Delia Preti, Serena Materazzi, et al.
Journal of Medicinal Chemistry|April 4, 2012
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implicationsPier Giovanni Baraldi, Delia Preti, Pier Andrea Borea, et al.
Bioorganic & Medicinal Chemistry|November 4, 2006
Hybrid molecules between distamycin A and active moieties of antitumor agentsPier Giovanni Baraldi, Delia Preti, Francesca Fruttarolo, et al.
Purinergic Signalling|April 30, 2008
Recent improvements in the development of A(2B) adenosine receptor agonistsPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Francesca Fruttarolo, et al.
Expert Opinion on Drug Discovery|March 19, 2013
Novel 8-heterocyclyl xanthine derivatives in drug development - an updatePier G Baraldi, Francesca Fruttarolo, Mojgan A Tabrizi, et al.
Purinergic Signalling|February 3, 2009
Recent improvements in the development of A(2B) adenosine receptor agonistsPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Francesca Fruttarolo, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Handbook of Experimental Pharmacology|January 29, 2019
NOP-Targeted Peptide LigandsDelia Preti, Girolamo Caló, Remo Guerrini
Expert Opinion on Therapeutic Patents|June 7, 2012
TRP channels as therapeutic targets in airway disorders: a patent reviewDelia Preti, Arpad Szallasi, Riccardo Patacchini
Pharmaceutical Patent Analyst|April 9, 2015
Transient receptor potential ankyrin 1 (TRPA1) antagonistsDelia Preti, Giulia Saponaro, Arpad Szallasi
Nature Chemical Biology|May 23, 2024
PROTAC-ing tuberculosisDelia Preti, Valentina Albanese, Peggy Carla Raffaella Marconi
Journal of Medicinal Chemistry|April 2, 2010
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agentsPier Giovanni Baraldi, Delia Preti, Serena Materazzi, et al.
Journal of Medicinal Chemistry|April 4, 2012
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implicationsPier Giovanni Baraldi, Delia Preti, Pier Andrea Borea, et al.
Bioorganic & Medicinal Chemistry|November 4, 2006
Hybrid molecules between distamycin A and active moieties of antitumor agentsPier Giovanni Baraldi, Delia Preti, Francesca Fruttarolo, et al.
Purinergic Signalling|April 30, 2008
Recent improvements in the development of A(2B) adenosine receptor agonistsPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Francesca Fruttarolo, et al.
Expert Opinion on Drug Discovery|March 19, 2013
Novel 8-heterocyclyl xanthine derivatives in drug development - an updatePier G Baraldi, Francesca Fruttarolo, Mojgan A Tabrizi, et al.
Purinergic Signalling|February 3, 2009
Recent improvements in the development of A(2B) adenosine receptor agonistsPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Francesca Fruttarolo, et al.
Pageof 10